77.92
+8.56(+12.34%)
Currency In USD
| Previous Close | 69.36 |
| Open | 69.18 |
| Day High | 83.22 |
| Day Low | 69 |
| 52-Week High | 94.9 |
| 52-Week Low | 13.22 |
| Volume | 3.39M |
| Average Volume | 1.5M |
| Market Cap | 4.49B |
| PE | -21.29 |
| EPS | -3.66 |
| Moving Average 50 Days | 49.73 |
| Moving Average 200 Days | 28.87 |
| Change | 8.56 |
If you invested $1000 in Structure Therapeutics Inc. (GPCR) since IPO date, it would be worth $2,996.92 as of January 14, 2026 at a share price of $77.92. Whereas If you bought $1000 worth of Structure Therapeutics Inc. (GPCR) shares 2 years ago, it would be worth $1,738.12 as of January 14, 2026 at a share price of $77.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
GlobeNewswire Inc.
Dec 17, 2025 1:30 PM GMT
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
GlobeNewswire Inc.
Dec 11, 2025 9:01 PM GMT
SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 10, 2025 4:15 AM GMT
SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today